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The repertoire of human αβ T-cell receptors (TCRs) is generated via somatic recombi-
nation of germline gene segments. Despite this enormous variation, certain epitopes
can be immunodominant, associated with high frequencies of antigen-specific T cells
and/or exhibit bias toward a TCR gene segment. Here, we studied the TCR repertoire of
the HLA-A*0201-restricted epitope LLWNGPMAV (hereafter, A2/LLW) from Yellow Fever
virus, which generates an immunodominant CD8+ T cell response to the highly effec-
tive YF-17D vaccine. We discover that these A2/LLW-specific CD8+ T cells are highly
biased for the TCR α chain TRAV12-2. This bias is already present in A2/LLW-specific
naı¨ve T cells before vaccination with YF-17D. Using CD8+ T cell clones, we show that
TRAV12-2 does not confer a functional advantage on a per cell basis. Molecular modeling
indicated that the germline-encoded complementarity determining region (CDR) 1α loop
of TRAV12-2 critically contributes to A2/LLW binding, in contrast to the conventional
dominant dependence on somatically rearranged CDR3 loops. This germline component
of antigen recognition may explain the unusually high precursor frequency, prevalence
and immunodominance of T-cell responses specific for the A2/LLW epitope.
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Introduction
Human αβ TCRs are heterodimeric proteins composed of an α- and
β-chain, somatically rearranged during T cell development from
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a selection of 176 variables (V), diversity (D), joining (J), and
constant (C) genes [1]. The specificity of peptide-MHC (pMHC)
recognition is conferred by the six highly flexible complementarity-
determining region (CDR) loops that make up the antigen-binding
site of the TCR. The CDR1 and CDR2 sequences are entirely
encoded within the Variable genes for each α- and β-chain (T cell
Receptor Alpha Variable, TRAV, and T cell Receptor Beta Variable
genes, TRBV, respectively). CDR1 and CDR2 are therefore entirely
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germline-encoded. In contrast, the CDR3 loops, which generally
make extensive contacts with the antigenic peptide [2, 3], are
encoded by the V(D)J joints and thus hypervariable. The general
consensus is that the somatic hypervariability of the CDR3 loops
contributes most to the broad range of TCR specificities. How-
ever, with more atomic structures of TCR-pMHC complexes, it is
becoming evident that the germline CDR1α loop can sometimes
also contact peptide residues, and in some cases dominate the
contact with the peptide [4–6].
Antigen-specific CD8+ T cells can be biased for certain TRAV
or TRBV segments or feature “public TCRs” shared across the
human population. In addition, TCR bias has been observed in
infection, autoimmunity, and alloreactivity, with many examples
reviewed by Turner et al. [7]. The reasons behind the sharing
of particular TCR segments are not yet fully understood but may
have critical implications for the understanding and induction of
optimal, protective antigen-specific T cell responses.
Recently, we described the remarkable decade-long persis-
tence of human stem cell-like memory (SCM) CD8+ T cells
specific for the HLA-A*0201-restricted Yellow Fever virus (YFV)
Non-Structural protein 4b214-222 epitope (sequence LLWNGPMAV;
hereafter, A2/LLW) in the context of YF-17D vaccination [8]. Sev-
eral studies have shown that this A2/LLW epitope is highly dom-
inant and prevalent amongst YF-17D vaccinees [9–11]. At the
peak of the T cell response, up to 25% of the peripheral CD8+
T cells can be specific for A2/LLW [9]. In our hands, A2/LLW-
specific CD8+ T cells could be detected in 38/41 HLA-A*0201
positive individuals after vaccination with YF-17D (>90% preva-
lence) [8]. Interestingly, we also revealed that na¨ıve A2/LLW-
specific CD8+ T cells were readily detectable in 3 out of 10 unvacci-
nated donors [8]. The reasons behind this unusual high frequency
and prevalence of A2/LLW-specific CD8+ T cells warranted further
investigation. Here, we show that A2/LLW-specific TCRs are highly
biased for the TCRα chain germline segment TRAV12-2. This find-
ing is in common with another human specificity for which there
is an extraordinarily high frequency of na¨ıve T cells: the HLA-
A*0201-restricted epitope ELAGIGILTV (heteroclitic analog to
EAAGIGILTV from Melan-A, and hereafter, A2/ELA) [12, 13].
Pertinently, A2/ELA-specific CD8+ T cells are also known to be
biased for TRAV12-2 and the germline-encoded CDR1α loop in
an A2/ELA-specific TCR featuring TRAV12-2 (MEL5 TCR) makes
major contributions to antigen recognition, thereby providing a
so called “innate-like” binding of the peptide [13–18]. We per-
formed functional and structural studies to further investigate the
TRAV12-2 bias in A2/LLW-specific CD8+ T cells.
Results
A2/LLW-specific CD8+ T cells are biased for the
segment TRAV12-2, before and after vaccination
Initially, genome-wide analysis of A2/LLW-specific CD8+ SCM
and various differentiation subsets in total CD8+ T cells [8, 19]
revealed that the most prominent feature was the highly signifi-
cant enrichment of the TRAV12-2 in A2/LLW-specific CD8+ T cells
(Fig. 1A). We next investigated this TRAV12-2 enrichment in
A2/LLW-specific CD8+ T cells from eight YF-17D vaccinees at the
protein level (Figs. 1B and E). We also compared A2/LLW-specific
CD8+ T cells in these vaccinees to those in unvaccinated donors
in order to address whether vaccination induced the observed
TRAV12-2 bias (Fig. 1E). In addition, we analyzed healthy donors
for other antigen specificities such as A2/ELA, which is known to
be biased for TRAV12-2 [13], and other viral antigen specifici-
ties that are not known to exhibit such bias: the HLA-A*0201-
restricted epitopes BMFL1 from Epstein Barr Virus (EBV) and
pp65 from cytomegalovirus (CMV) as well as two other YF epi-
topes that were detectable in two YF-17D vaccinees (the HLA-
A*0201-restricted VMLFILAGL from NS4a protein, A2/VML, and
HLA-B*07-restricted RPIDDRFGL from NS5 protein, B7/RPI). In
accordance with our previous study [8], we found that vaccinees
had easily detectable and largely differentiated A2/LLW-specific
CD8+ T cells (Figs. 1B to D), while unvaccinated donors showed
lower but detectable frequencies of na¨ıve A2/LLW-specific CD8+
T cells (i.e. above 0.001%) (Figs. 1C and D). As expected, na¨ıve
A2/ELA-specific CD8+ T cells were also detectable in healthy
donors, while the other viral antigen specificities were variably
detected amongst donors and displayed differentiated phenotypes
(Figs. 1C and D). The TRAV12-2 segment was used by the major-
ity (median 55.5%) of A2/LLW-specific CD8+ T cells (Fig. 1E), in
contrast to total CD8+ T cells (median 12.5%). The TRAV12-2 bias
reached a similar extent as in Melan-A-specific CD8+ T cells from
healthy donors (median 57.7%), in contrast to the absence of bias
in the other specificities (other two YF-17D epitopes and CMV-
and EBV-specific epitopes) (Fig. 1E). Interestingly, we found that
the TRAV12-2 bias was already evident in na¨ıve A2/LLW-specific
CD8+ T cells, prior to vaccination (median 69.2%).
Despite the TRAV12-2 bias, A2/LLW-specific TCRs are
mostly unique and public sequences infrequent
We generated and analyzed 57 A2/LLW-specific CD8+ T cell
clones derived from four different YF-17D vaccinees. As shown in
Fig. 2A, the Vα gene segments were predominated by TRAV12-2,
with 45 of 57 clones positive for TRAV12-2 (78.9%). The TRAJs
were relatively more diverse, using 15 of the 61 TRAJ human
genes, yet consisting predominantly of the TRAJ30 (45.1%) (Fig.
2B). In contrast, the Vβ repertoire was highly heterogeneous,
with 10 different Vβ segments used, although a moderate bias for
some TRBV genes was noted: TRBV9 was used by 16 clones and
TRBV2 used by 10 clones (Fig. 2C). There was no evident TRBJ
bias (Fig. 2D). In addition, TRAV12-2 CDR3 length consisted pre-
dominantly of 8 amino acids whereas CDR3β sequences showed a
broader distribution (Fig. 2E). Most TCRs were unique clonotypes
(Supporting Information Table 1), with no conserved motif in the
CDR3 loop observed. We identified two public TRAV sequences:
“CAVTDDKIIFG” was shared by all four donors and
“CAVGDDKIIFG” by three out of four donors.
C© 2017 The Authors. European Journal of Immunology published by
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Figure 1. A2/LLW-specific CD8+ T cells are strongly biased for TRAV12-2 similarly to A2/ELA-specific CD8+ T cells. (A) TRAV12-2 mRNA
expression in A2/LLW-specific stem cell-like (SCM) CD8+ T cells compared to reference differentiation subsets in total CD8+ T cells (N
= 8 YF-17D vaccinees), including: Naı¨ve, SCM, central memory (CM) and effectors (E). Samples were isolated from PBMCs by FACS and
total RNA analyzed by microarray. (B) Representative gating strategy for the flow cytometry analysis of CD8+ T cell subsets in total
or tetramer positive populations and TRAV12-2 expression therein. EM: effector memory; EMRA: effector memory CD45RA+. (C) Fre-
quencies (%) of various antigen specificities amongst circulating CD8+ T cells (mean and SEM), including A2/LLW in YF-17D vaccinees
(N = 8) and unvaccinated individuals (N = 5), A2/VML (N = 2) and B7/RPI (N = 2) in YF-17D vaccinees, as well as A2/CMV (N = 8; stars repre-
sent CMV-seronegative donors = 5/8), A2/EBV (N = 8) and A2/ELA (N = 8). Data are representative of two independent experiments. (D) Subset
distribution of antigen-specific CD8+ T cell populations (mean and SEM). (E) Subject-paired comparison of TRAV12-2 expression between antigen-
specific and total CD8+ T cells (“vac.” = YF-17D vaccinee; “unv.” = unvaccinated with YF-17D).
C© 2017 The Authors. European Journal of Immunology published by
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Figure 2. TCR repertoire analysis of A2/LLW-specific CD8+ T cell clones generated from four vaccinated donors. Total RNA was isolated from 57
A2/LLW-specific CD8+ T cell clones, cDNA prepared, analyzed by PCRwith primers specific for each TRAV and TRBV gene segment, and sequenced.
(A) TRAV gene usage. (B) TRAJ gene usage. (C) TRBV gene usage. (D) TRBJ gene usage. (E) CDR3 length distribution according to IMGT definition.
On a per cell basis, TRAV12-2 does not confer
functional advantages to A2/LLW-specific CD8+ T cells
One hypothesis could be that TCRs with TRAV12-2 mediate
increased T cell function. Analysis of various functional proper-
ties in A2/LLW-specific CD8+ T cell clones showed that TRAV12-
2-positive clones did not differ from TRAV12-2-negative clones,
whether in killing capacity (EC50 in Fig. 3A), TCR avidity (Koff
in Fig. 3B) or degranulation and secretion of IFN-γ, TNF-α, and
IL-2 after 4-hours peptide stimulation (Fig. 3C and D). Altogether,
expression of TRAV12-2 did not confer a particular functional
advantage in A2/LLW-specific CD8+ T cell clones.
The LLW peptide binds with high stability
to HLA-A*0201
The TRAV12-2 bias in A2/LLW-specific TCRs is reminiscent of
the TRAV12-2 bias observed in A2/ELA-specific CD8+ T cells. In
the A2/ELA-specific MEL5 TCR structure, the germline-encoded
CDR1α loop makes important interactions with the ELA peptide
in complex with HLA-A*0201 providing an explanation for the
preferential TRAV12-2 usage and high frequency of this speci-
ficity [5, 14–16, 20–22]. In order to determine the structural char-
acteristics that govern the TCR recognition of the LLW peptide,
we intended to solve the crystal structure of a TRAV12-2 posi-
tive TCR specific for A2/LLW in complex with its cognate pMHC
(A2/LLW). Unfortunately, despite several attempts with differ-
ent TCRs, we were unable to refold a functional A2/LLW-specific
TRAV12-2 positive TCR. We were able to solve the atomic struc-
ture of the A2/LLW pMHC complex at 1.59A˚ resolution. Electron
density around the peptide was unambiguous (Fig. 4A). The gen-
eral features of the binding are similar to those observed in other
peptide-HLA-A*0201 complexes: the nonamer adopts a confor-
mation with central bulge between residues at position 4 and 6
where the side chains are protruding toward the TCR (Fig. 4B),
while the peptide termini provide binding into the HLA binding
pockets with many specific interactions (Figs. 4A and C).
To assay more directly the peptide binding affinity, we per-
formed circular dichroism (CD) temperature melting experiments.
C© 2017 The Authors. European Journal of Immunology published by
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Figure 3. TRAV12-2 expression does not confer a functional advantage. Functional properties of A2/LLW-specific CD8+ T cell clones were assessed
by various methods. (A) Killing capacity (51-chromium release assay) with LLW peptide titration in A2/LLW-specific CD8+ T cell clones (TRAV12-2
positive N = 37, TRAV12-2 negativeN = 10). Data are representative of two independent experiments (mean and SEM; t-test p value). (B) Monomeric
dissociation constant (Koff) rates measured in CD8+ T cell clones (TRAV12-2 positive N = 25, TRAV12 negative = 8) using NTAmers (mean and SD;
t-test P value). (C and D) Intracellular cytokine staining of CD8+ T cell clones (TRAV12-2 positive N = 11, TRAV12-2 negative N = 6) following LLW
peptide stimulation for 4 h, showing representative flow cytometry gating strategy in C. Data are representative of two independent experiments.
The A2/LLW complex showed a melting temperature Tm of 66.5°C
and transition enthalpies HvH of ca. −500 kJ/mol (Fig. 5). Thus,
the A2/LLW complex is very stable when compared to other pMHC
complexes that are also recognized by TRAV12-2 positive TCRs
(Tm / HvH 66.0°C/-610 kJ/mol and 63.0°C/-380 kJ/mol for
A2/Tax from the human T-lymphotropic virus type 1 (HTLV-1)
and A2/ELA, respectively).
The germline-encoded CDR1α loop of TRAV12-2
contributes to pMHC binding
To investigate the structural determinants of a TRAV12-2 positive
TCR interacting with A2/LLW, we supported our experimental
A2/LLW crystal data with two complementary strategies. First,
we combined our structure of the A2/LLW and the previously
C© 2017 The Authors. European Journal of Immunology published by
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Figure 4. LLW peptide binds stably to HLA-A*0201. (A) Electron density at 1σ contour level around the peptide of the A2/LLW complex showing
the overall conformation of the peptide. Blue arrows (TCR-exposed) and orange arrows (MHC-buried) indicate direction of amino acid side chains.
(B) Surface and stick representation of HLA-A*0201 and peptide residues, respectively. (C) LIGPLOT schematic diagram showing the various
interactions of the LLW peptide with HLA-A*0201. Purple lines are peptide covalent bonds, orange lines are HLA-A2 covalent bonds, dotted green
lines are polar/H-bond contacts, and open red arcs indicate a protein atom in a non-polar contact.
Figure 5. Thermal stability of pMHCs. (A) Temperature stability of
the HLA-A2*0201 molecules with the ELA (ELAGIGILTV, square/straight
line), Tax (LLFGYPVYV, triangles/dashed line), LLW (LLWNGPMAV,
close circles/dash-dotted line), and LLW-4A (LLWAGPMAV, open cir-
cles/dashed line) peptides assayed by circular dichroism spectroscopy.
Lines represent data fits as described in Methods. (B) Apparent melting
temperature Tm and van’t Hoff’s enthalpy of unfoldingHvH (mean and
SD). Errors bars represent S.D. resulting from the multivariable curve
fitting.
solved structures of the MEL5 TCR to perform in silico mod-
eling of the A2/LLW-specific YF5048 TCR (TRAV12-2/TRBV9;
Fig. 6A and Supporting Information Table 2). This A2/LLW-
specific TCR from clone 5048 NN4 (hereafter YF5048) was chosen
out of our A2/LLW-specific clone database due to its closest sim-
ilarity to the MEL5 TCR sequence for the α chain (just 3 amino
acids different; Supporting Information Fig. 1A). The overall con-
formation of the LLW peptide binding to the MHC molecule is
similar to the ELA peptide thus facilitating the modeling (Support-
ing Information Fig. 1B). Figure 6A and Supporting Information
Table 2 show the molecular interactions taking place between the
TRAV12-2 TCR and the A2/LLW complex. In this model, most
of the interactions between the TCR and the peptide originate
from the α chain encoded by TRAV12-2. Five peptide residues
are pointing toward the TCR: Leu1, Asn4, Gly5, Met7 and Ala8;
and these predominantly contact the CDR1α loop. In particular,
Asn4 extends into a polar pocket of TRAV12, where its side chain
is making a network of hydrogen bonds with the side chains of
CDR1α Ser32 and CDR3α Asp92, as well as non-polar interactions
with CDR1α Gln31. In turn, the CDR3β loop of YF5048 expands
between the Asn4 and Met7 peptide residues, and exchanges
two hydrogen bonds between the backbone of Ser98 and the
C© 2017 The Authors. European Journal of Immunology published by
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Figure 6. Molecularmodeling indicates that germline-encodedCDR1 in
TRAV12-2 makes major contributions to the binding with the A2/LLW
complex. Calculated 3D structure of the YF5048 TRAV12/TRBV9 TCR
bound to the HLA-A2/LLWpeptide complex (A) and experimental struc-
tures of the MEL5 TRAV12/TRBV30 TCR bound to HLA-A2/ELA peptide
complex, PDB ID 3G1 (B) or the HLA-A2/Tax peptide complex, PDB ID
4FTV (C), with ribbons representing α- and - β chains in dark and light
orange, respectively; the MHC molecule in tan ribbon, and peptides in
ball and stick representation. TCR and MHC side chains are shown in
thick lines, with carbon atoms colored in orange and tan, respectively.
Hydrogen bonds are displayed as magenta thin lines.
backbones of peptide residues Gly5 and Pro6 (Fig. 6A). This 3D
model of A2/LLW/YF5048 presents important structural similari-
ties with the experimental structures of the ELA and Tax peptides
(Fig. 6). The backbone of the 3 first and last residues are nearly
superimposed, and the corresponding side chains occupy the same
MHC pockets: Leu2 of LLW, ELA and Tax in P2; Ala8 of LLW, Thr9
of ELA and Tyr8 of Tax in P8; Val9 of LLW and Tax, and Val10 of
ELA in P9. In line with this, residues Leu1 of LLW, and Glu1 of ELA
are facing the TCRα, while Met7 of LLW, Leu8 of ELA and Val7
of Tax are pointing toward the TCRβ. Important structural differ-
ences arise for the central residues of the peptides. While pocket
P3 of MHC is occupied by Trp3 of LLW and Phe3 of Tax, it is occu-
pied by Gly6 and part of the Ile5 backbone of the ELA peptide,
due to a large backbone rearrangement. In addition, the peptide
residue pointing toward TCRα and possibly making interactions is
Asn4 for LLW, Ile5 for ELA and Tyr5 for Tax.
The second strategy to investigate the structural determinants
of the A2/LLW-specific TRAV12-2 was to functionally interrogate
the A2/LLW-specific CD8+ T cell clone YF5048 using amino acid
substitutions of the LLW index peptide and combinatorial peptide
library (CPL) screening. Alanine substitutions at each position of
the LLW peptide revealed that the central region of the peptide
(positions 3–5) was key for TCR recognition as these substitu-
tions were deleterious to recognition; in particular the Asn4→Ala4
(LLW-4A) was very informative as it completely abrogated the
response of the YF5048 clone (Fig. 7A). This suggested that the
TCRmakes the majority of its critical contacts in the central region
of the peptide, which is consistent with the conformation of the
peptide accommodating into a central bulge (Figs. 4A and B). The
dramatic effect of the Asn4→Ala4 mutation is in line with the crit-
ical interactions made by the TRAV12-2 CDR1α loop of the TCR
with the Asn (Fig. 6A and Supporting Information Table 2). Inter-
estingly, both A2/LLW and the mutated A2/LLW-4A complexes
were found to have the same Tm of 66.5°C, ruling out the possi-
bility that the absence of response to the mutated peptide LLW-4A
is a consequence of the instability of its complex with HLA-A*02
(Fig. 5).
To further explore the observations of the alanine scan we per-
formed a nonamer CPL screen of the YF5048 clone, which revealed
positions of the peptide where index residues gave similar (posi-
tions 1, 4 and 6) or superior (positions 2, 3, 5 and 9) activation
compared to non-index amino acids (Fig. 7B). In contrast, index
residues were seen minimally at positions 7 and 8, with relatively
high responses seen in both cases for non-index amino acids (Fig.
7B). In concordancewith the alanine scan in the LLWpeptide back-
bone, activation toward the index residues at positions 3 (Trp) and
5 (Gly) were dominant over the other amino acid residues. Despite
the dramatic loss of YF5048 activation toward the Asn4→Ala4 in
the index peptide, non-index residues (namely Arg, Thr and Trp)
also gave activation that was comparable or superior (Arg) to the
Asn at position 4 (Fig. 7B). In light of this result, we performed
an Asn4→Arg4 substitution of the index peptide, which ablated
recognition of the peptide by YF5048 (Supporting Information
Fig. 3A and 3B) and therefore supported the previous data that
showed the importance of the Asn4 for TCR recognition. The loss
C© 2017 The Authors. European Journal of Immunology published by
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Figure 7. Peptide recognition signature of an individual TCR derived from clone YF5048. The A2/LLW-specific CD8+ T cell clone YF5048 was
functionally interrogated using amino acid substitutions of the LLW index peptide and CPL screening (A) Alanine-scan of the LLW peptide
assessed by MIP-1β activation with graded concentrations of the peptides (mean and SEM). Data are representative of 2 independent experiments.
(B) Nonamer CPL scan for clone YF5048 assayed by MIP-1β activation (mean and SD). Index peptide residues are represented as dashed-pattern
bars. Upwards arrows (TCR-exposed) and downwards arrows (MHC-buried) indicate direction of amino acid side chains. Data are representative
of 3 independent experiments.
of reactivity toward the peptide LLWRGPMAV suggested that the
Asn4→Arg4 substitution alone was not sufficient to be seen by the
TCR and required further amino acid changes at other positions
of the index peptide to achieve activation. The ability of a CPL to
identify amino acids that can be substituted and recognized by a
clonewas demonstrated using second TRAV12-2 positive A2/LLW-
specific clone, YF5031. CPL data for YF0531 showed that this clone
preferred the index residue sub-libraries at the central positions
of the peptide (Supporting Information Fig. 2A), akin to YF0548
(Fig. 7B). Maintaining this central region with substitutions at
5 other positions (KQWNGFIPV) substitutions in bold and under-
lined) gave a peptide sequence that activated YF0531 (Supporting
Information Fig. 3C), thereby further highlighting the importance
of the central residues for TRAV12-2 TCR recognition of the YF
peptide. We also performed CPL screening of TRAV12-2 negative
clones to explore their reactivity toward the central region of the
peptide. Whereas the TRAV12-2 positive clones YF5048 (Fig. 7B)
and YF5031 (Supporting Information Fig. 2A) were focused on
index residues Trp3 and Gly5, TRAV12-2 negative clone YF5001
recognized index and multiple non-index amino acid residues at
C© 2017 The Authors. European Journal of Immunology published by
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Figure 8. Absence of cross-reactivity between A2/LLW and A2/ELA epitopes. Recognition of the LLW and ELA peptides by A2/LLW-specific and
A2/ELA-specific CD8+ T cell clones was assessed by chromium release assay. (A) Cross-reactivity analysis of TRAV12-2 positive A2/LLW-specific
CD8+ T cell clones toward the LLWNGPMAV (LLW, solid line) and ELAGIGLTV (ELA, dashed line) (mean and SD). (B) Cross-reactivity analysis
of TRAV12-2 positive A2/ELA-specific CD8+ T cell clones toward the LLWNGPMAV (LLW, solid line) and ELAGIGLTV (ELA, dashed line) (mean
and SD).
these positions. Although YF5001 recognized the Asn4 sub-library,
other amino acid sub-libraries (Ile, Arg and Try) were of compa-
rable or greater potency (Supporting Information Fig. 2B). The
second TRAV12-2 negative clone YF5048NN1, however, exhib-
ited a focused recognition across the central region of the peptide;
preferring only Trp (index) at position 3, and Gly (index) or Thr
(non-index) at position 5 (Supporting Information Fig. 2C). Inter-
estingly, any response by YF5048NN1 toward the TRAV12-2 TCR
critical Asn at position 4 was unconvincing and instead domi-
nated by activation toward the Ser-fixed sub-library (Supporting
Information Fig. 2C). Taken together these data further support
the importance of the central amino acid residues, especially the
Asn4, of the LLW peptide in the binding of TRAV12-2 positive
TCRs.
In conclusion, the complementary approaches of modeling
and cell functional assays demonstrated the key elements that
mediate the TRAV12-2 positive YF5048 TCR interaction with the
A2/LLW complex and support that the germline-encoded CDR1α
loop of TRAV12-2 makes critical contributions to cognate peptide
recognition.
A2/LLW and A2/ELA TRAV12-2 positive TCRs
preserve their respective specificity
Given the germline nature of the CDR1α loop of TRAV12-2 that
is critical to peptide recognition of both A2/LLW and A2/ELA
specificities, we addressed whether there was any cross-reactivity
between T-cells with these TRAV12-2-dominated specificities. The
TRAV12-2 positive A2/LLW-specific clones did not respond to
the ELA peptide (Fig. 8A) and the TRAV12-2 positive A2/ELA-
specific clones did not respond to the LLW peptide (Fig. 8B) indi-
cating there was no common, shared TRAV12-2-mediated mode
of antigen recognition. These functional data were supported by
in silico modeling of the MEL5 TCR together with the A2/LLW
complex showing unfavorable interactions (Fig. 9A). In fact, the
most important difference in the interaction scheme of A2/LLW
with the A2/LLW-specific YF5048 TCR versus with the A2/ELA-
specific MEL5 TCR involves the CDR3β loop. In the A2/LLW/MEL5
structural model, the Asn4 residue of the LLW peptide is situated
close to the Leu98 residue of the CDR3β loop. The contact between
the backbone carbonyl of Asn4 and the side chain of Leu98 prevent
the former from making any hydrogen bond with its surrounding,
and is unfavorable to the binding between A2/LLW and MEL5
(Fig. 9A). In contrast, in the A2/LLW/YF5048 structural model,
the key residue in CDR3β loop is Gly97, which does not sterically
hinder the backbone carbonyl of the peptide Asn4 residue (Fig.
9B). In the A2/ELA/MEL5 structure, due to a different position
of the peptide backbone, the Gly4 residue of ELA (corresponding
to Asn4 in LLW) is situated far from Leu98 in the CDR3β loop,
and its backbone carbonyl is unhindered by this non-polar side
chain (Fig. 9C). This key difference in the CDR3β loops explains
the unfavorable interaction between MEL5 and A2/LLW, compat-
ible with the lack of cross-reactivity observed between TRAV12-
2 positive TCRs toward LLW or ELA. These data highlight the
importance that the CDR3β loop plays in TCR specificity as
although this loop plays a minimal role in pMHC contact it can act
to interfere with engagement.
Discussion
In this study, we analyzed the TCR repertoire of CD8+ T cells
specific for the immunodominant A2/LLW epitope in YF-17D vac-
cinees and controls. We revealed and quantified the TRAV12-2
bias in A2/LLW-specific CD8+ T cells. Various functional assays
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Figure 9. Calculated structures of theMEL5 andYF50408 TCRs bound to
the HLA-A2/LLWpeptide complex and the experimental 3D structure of
the MEL5 TCR bound to the HLA-A2/ELA peptide complex. Calculated
structures of the MEL5 and YF50408 TCRs bound to the HLA-A2/LLW
peptide complex, (A) and (B), respectively. Experimental 3D structure
of the MEL5 TCR bound to the HLA-A2/ELA peptide complex (C). Repre-
sentation: α and β chains are in dark and light orange ribbons, respec-
tively; the MHC molecule in tan ribbon; peptides in ball and stick; TCR
side chains in thick lines representation, with carbon atoms colored
in orange; the transparent surfaces of Asn4 (of LLW) or Gly4 (of ELA),
in contact with CDR3 Leu98 (MEL5) or Gly97 (YF5048), are colored in
magenta.
using T-cell clones demonstrated that TRAV12-2 does not pro-
vide a functional advantage on a per cell basis. Together with
the fact that this strong TRAV12-2 bias was already present in
na¨ıve A2/LLW-specific CD8+ T cells before YF-17D vaccination, it
rather suggests that TRAV12-2 might confer a selective advantage
for high frequency and prevalence by favoring thymic output of
na¨ıve cells. We thus sought to investigate how TRAV12-2 may pro-
vide such advantage by investigating the mode of antigen binding
and structural considerations of the TCR-peptide-MHC complex.
The A2/ELA epitope represents a well-known model anti-
gen for which T cells are biased for TRAV12-2 usage [13–17].
A2/ELA-specific CD8+ T cells exhibit high frequency and preva-
lence in HLA-A*0201 healthy individuals as well as melanoma
patients, showing na¨ıve and differentiated phenotypes, respec-
tively. Intriguingly, the binding between the MEL5 TCR express-
ing TRAV12-2 and the ELA peptide in complex with HLA-A*0201
occurs via dominant contacts with the CDR1 loop of TRAV12-
2 [13, 18, 21, 22]. The TRAV12-2 gene is also expressed by the A6
TCR, which is specific for the A2/Tax epitope of the HTLV-1 [4].
The CDR1α and CDR2α loops of the A6 TCR utilize an antigen-
binding mode virtually identical to that seen in the MEL5-A2/ELA
complex, making contacts between the CDR1α loop and the Tax
peptide. A study in HTLV-I-Associated Myelopathy/Tropical Spas-
tic Paraparesis (HAM/TSP) patients revealed that TRAV12-2 tran-
scripts are predominant [23] and the frequency of na¨ıve cells with
this specificity is very high [24]. Therefore, A2/Tax-specific CD8+
T cells constitute another documented example of high na¨ıve fre-
quency associated with TRAV12-2 bias.
Unfortunately, our extensive attempts to generate a TRAV12-2
TCR A2/LLW co-crystal structure failed so we resorted to molec-
ular modeling of this interaction taking advantage of the high
sequence similarity between the A2/LLW-specific TCR YF5048 and
the A2/ELA-specific TCR MEL5. Conveniently, the LLW peptide in
the free A2/LLW structure we solved adopts a similar conforma-
tion to the ELA peptide in the A2/ELA/MEL5 TCR complex. Mod-
eling showed that the YF5048 TCR α-chain positioned above the
N-terminus of the peptide, making contacts predominantly with
Asn4 in the middle of the peptide via the CDR1α loop of TRAV12-
2. The importance of this interaction is further supported by our
results from the mutagenesis scan across the LLW peptide and
CPL screen, highlighting Asn4 as a critical residue for TCR recog-
nition by TRAV12-2 positive TCRs. Our modeling data suggests
that the germline-encoded TRAV12-2 CDR1α loop of A2/LLW-
specific CD8+ T cells makes critical contacts with both MHC and
peptide in a comparable manner to the CDR1α loops in the MEL5
and A6 TRAV12-2 positive TCRs; the MEL5 and A6 [4, 18]. These
three paralleled examples of TRAV12-2 biased responses endorse
the concept that the interactions between the TCR and the antigen
can rely substantially on TCR segments that already pre-exist in
the germline rather than on somatic CDR3 rearrangement. How-
ever, it is important to note that this observation does not apply
to all immunodominant T cell responses, as many public TCRs or
immunodominant epitope-specific TCRs bind their cognate pep-
tide predominantly via residues encoded in the CDR3 rearranged
loops [6, 25].
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Importantly, we showed that TCRs sharing this heritable
TRAV12-2 CDR1α component of antigen binding still preserve
their respective antigen specificity. Indeed, we demonstrated that
there is no cross-reactivity between the LLW and ELA specificities.
Based on in silico modeling, the CDR3β loop sterically hindered
engagement of the non-cognate peptide. Thus, even these exam-
ples of a TRAV germline-encoded antigen binding mode are still
heavily reliant on permissive sequences within the TRBV non-
germline CDR3 loop.
It is intriguing that these three examples of TCRs binding their
epitope with a germline component all involve the CDR1α loop
of TRAV12-2 and HLA*0201. It is conceivable that TCRs express-
ing the TRAV12-2 could have a selective advantage for binding
to cognate antigen restricted by HLA-A*0201 or that other anti-
gen specificities (not only restricted by HLA-A*0201) also har-
bor biases for certain germline-encoded TCR segments but that
these have not yet been identified. The HLA-A*0201 allele and
its associated antigen specificities are the most studied because
HLA-A*0201 is prevalent at 30–50% in Caucasian populations
and is the most prevalent HLA subtype amongst the global human
population, potentially inducing a research bias [26]. Indeed, the
TCR/pMHC structural database is dominated by interactions with
HLA A2. More studies need to be conducted to appreciate the
extent to which this phenomenon of germline-encoded TCR recog-
nition applies to other specificities and TRAV/TRBV families.
Despite the tremendous theoretical genetic diversity of the TCR
repertoire, most studies showed that the adult TCR repertoire is
a consequence of a process that is far from random and TCR
bias is commonly found in immune responses [27]. A specificity
and/or TCR bias could reflect an evolutionary advantage during
infection and other diseases. Several lines of evidence indicate
that the germline-encoded TCR segments have features that pro-
mote binding to MHCmolecules, suggesting co-evolution between
TCR and MHC molecules [28–30]. Our data suggests that there
is also co-evolution between the TCR and the cognate peptide.
Indeed, we observed that TRAV12-2 TCR bias is present before
YF-17D vaccination. In agreement with our functional studies on
A2/LLW-specific clones, it was reported that TRAV12-2 usage in
A2/ELA-specific CD8+ T cells was independent from functional
avidity [15]. In fact, the origin of the large na¨ıve A2/ELA-specific
CD8+ T cell population was attributed to preferential thymic selec-
tion [31, 32]. Given that antigen recognition features a germline-
encoded component, there is presumably a genetic advantage that
confers higher chances for thymic output of TCR constructions
involving the CDR1α of TRAV12-2. Thus, although TRAV12-2 does
not confer a functional advantage on a per cell basis, it may provide
an advantage at the level of the organism by skewing the na¨ıve
CD8+ T cell compartment toward these specificities recognized by
TRAV12-2 CDR1α. This possibly explains the high frequency and
prevalence of specificities such as A2/LLW and A2/ELA.
In summary, we discovered the TCR bias for TRAV12-2 in
A2/LLW-specific CD8+ T cells and demonstrated that there is
no functional advantage in featuring TRAV12-2 on a per cell
basis. Rather, our structural modeling suggests that the germline-
encoded CDR1α loop centrally contributes to peptide binding
similar to two other TRAV12-2 positive TCR specificities. We
also demonstrated that TCRs sharing this TRAV12-2 CDR1α –
mediated mode of antigen binding still preserve their own antigen
specificity.
Materials and methods
Peripheral blood samples
All PBMC samples were obtained in the framework of our previ-
ously published clinical study, approved by the Human Research
Ethics Committee of the Canton de Vaud (protocol 329/12) with
healthy volunteers participating under written informed consent
[8].
Generation of T cell clones
All A2/LLW-specific CD8+ T cell clones used in this study were
generated in the laboratory of D. Speiser, derived from 4 healthy
YF-17D (Stamaril, Sanofi Pasteur) vaccinees. Purified A2/LLW
tetramer-positive populations were isolated by FACS as described
[8] and cloned by limiting dilution in Terasaki plates, cultured in
RPMI 1640 medium supplemented with 8% human serum and
150 U/mL recombinant human IL-2 (rIL-2). Thereafter, T cell
clones were expanded by periodic restimulation with 1 μg/mL
PHA and 106/mL irradiated allogeneic PBMC (30 Gy) as feeder
cells. The MEL5 clone was generated in the laboratory of A.
Sewell as previously described [18]. The clones HD421 2/5F and
LAU1264 were generated in the laboratories of D. Speiser and N.
Rufer as previously described [15].
TCR repertoire and clonotype analysis
in A2/LLW-specific CD8+ T cell clones
Total RNA was isolated using the PicoPure RNA kit per manu-
facturer’s instructions, and cDNA prepared and sequenced as pre-
viously described [21]. Briefly, for the Vβ repertoire, each cDNA
sample was subjected to individual PCRs using a set of previously
validated forward primers specific for the 22 TRBV subfamilies and
one reverse primer specific for the corresponding Cβ gene segment.
For the Vα repertoire, we amplified and sequenced the TRAV12-2
segment using the TRAV12 (forward) and TRAC (reverse) primers.
PCR amplicons of interest were sequenced from the reverse primer
by Fasteris S.A. TRAV and TRBV segments were described accord-
ing to the IMGT nomenclature [33].
51Chromium release assays
The HLA-A*02+ human mutant cell line CEMx721.T2 (Ameri-
can Type Culture Collection) was used as target by labeling with
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51Cr for 1 h at 37°C, followed by extensive washing. Target cell
killing was assessed by chromium release in the supernatant upon
co-culture with CD8+ T cell clones (effector cells) at the Effec-
tor:Target ratio of 10:1 for 4 h at 37°C in V-bottom microwells,
in presence of serial dilutions of the peptide (LLWNGPMAV or
ELAGIGILTV), measured using a gamma counter and calculated
as:
% specific lysis = 100 × (experimental − spontaneous release)
(total − spontaneous release)
Flow cytometry
CD8+ T cells were first enriched from cryopreserved sam-
ples using the human CD8+ T cell enrichment kit from
StemCell Technologies (negative selection, per manufacturer’s
instructions). Stainings were performed using phosphate-buffered
saline with 5 mM EDTA, 0.2% bovine serum albumin,
and 20 mM sodium azide [fluorescence-activated cell sort-
ing (FACS) buffer]. Tetramer stainings were performed for
40 min at 4°C. All tetramers were purchased from TCmetrix
Sa`rl : HLA-A*0201/LLWNGPMAV (NS4b214-222, Yellow Fever
Virus), HLA-A*0201/VMLFILAGL (NS4a54-62, Yellow Fever Virus),
HLA-B*0701/RPIDDRFGL (NS5211-219, Yellow Fever Virus),
HLA-A*0201/GLCTLVAML (BMFL1280-288, Epstein Barr Virus),
HLA-A*0201/NLVPMVATV (pp65495-503, Cytomegalovirus), HLA-
A*0201/ELAGIGILTV (Melan-A26-35 (A27L), Melanoma). Surface
antibody staining was then performed, followed by staining
with LIVE/DEAD-Fixable-Aqua (Invitrogen), each step at 4°C for
30 min. Cells were fixed overnight in 0.36% formaldehyde (sup-
plemented with 2% glucose and 5 mM sodium azide). Samples
were acquired using a Gallios flow cytometer (Beckman Coulter,
three-laser configuration). The data were processed with FlowJo
(Tree Star Inc., v9.5.2). Samples with antigen-specific populations
below 0.001% tetramer-positive cells in total CD8+ T cells were
considered negative and populations consisting of less than 20
events were not considered eligible for further analysis.
Intracellular cytokine staining assay
A2/LLW-specific CD8+ T cell clones were stimulated with LLW
peptide-loaded T2 cells at the E:T cell ratio of 1:2 for 4 h at
37°C in the presence of Brefeldin-A (Sigma-Aldrich) and anti-
CD107a-FITC antibody (BD Biosciences). Then, cells were stained
with anti–CD8–APC-AF750 antibody (Beckman Coulter) at 4°C
for 30 min. After washing in PBS, cells were incubated with
LIVE/DEAD-Fixable-Aqua (Invitrogen) at 4°C for 30 min, and
fixed at 4°C overnight (0.36% formaldehyde buffer). Cells were
washed and stained intracellularly with anti-IFNγ-PC7, anti-TNFα-
A700 and anti-IL-2-PerPCP-Cy5.5 antibodies (BD Biosciences) in
FACS buffer with 0.1% saponin for 30 min at 4°C. Samples were
acquired and data processed as described above.
NTAmer staining and dissociation kinetic
measurements
Dually labeled pMHC multimers built on NTA-Ni2+-His-tag inter-
actions called NTAmers (synthetized by TCMetrix Sa`rl) were used
for dissociation kinetic measurements [34, 35]. Stainings with
dually PE- and Cy5-labeled A2/LLW-specific NTAmers and data
analysis were done as previously described [34, 36]. Briefly, stain-
ing was measured at 4°C using a thermostat device on a SORP-
LSR II flow cytometer (BD Biosciences). Following 30 s of baseline
acquisition, imidazole (100 mM) was added. PE and Cy5 fluores-
cence were measured during the following 5 min. Data were pro-
cessed using the kinetic module of the FlowJo software (v.9.7.6;
Tree Star), and corrected mean fluorescence intensity values were
plotted and analyzed using the GraphPad Prism software (v.6;
GraphPad).
Combinatorial peptide library (CPL) scans
The nonamer CPL contains a total of 4.8 × 1011 ((9+19) × 198)
different nonamer peptides divided into 180 sub-libraries with
each containing 198 different nonamer peptides in approximately
equimolar concentrations (Pepscan, Lelystad, The Netherlands)
[37]. Each of the 180 sub-libraries has a fixed amino acid residue
but all other positions are degenerate. Cysteine was excluded from
all degenerate positions to avoid oxidation, but was included at
the fixed positions. Prior to the assay, CD8+ T cell clones were
washed and rested overnight in R5 medium (RPMI 1640 supple-
mented with 100 units/mL penicillin, 100 μg/mL streptomycin,
2 mm l-glutamine, and 5% heat-inactivated fetal calf serum (all
Invitrogen). For CPL screening, 6 × 104 C1R A2 cells [38] were
pulsed with each sub-library at 100 μg/mL in duplicate for 2 h
at 37°C. After peptide pulsing, 3 × 104 CD8+ T cells were added,
and the cultures were incubated overnight at 37°C. Subsequently,
the supernatant was harvested and assayed for MIP-1β by ELISA
according to the manufacturer’s instructions (R&D Systems).
Protein expression, refolding, and purification
HLA A*0201 α-chain and β2m were expressed separately, with-
out post-translational modification, as insoluble inclusion bodies
(IBs) in competent Rosetta (DE3) Escherichia coli cells, using 0.5M
IPTG to induce expression as thoroughly described recently [39].
Briefly, for a 1L pMHC refold, 30 mg HLA-A*0201 α-chain was
mixed with 30 mg β2 m and 4 mg peptide at 37°C for 15 min
with 10 mM DTT. This mixture was then added to cold refold
buffer (50 mM Tris, pH8, 2 mM EDTA, 400 mM L-arginine, 6 mM
cysteamine hydrochloride, and 4 mM cystamine). Refolds were
mixed at 4°C for > 6 h. Dialysis was performed against 10 mM
TRIS, pH8.1, until the conductivity of the refolds was less than
two millisiemens per centimeter. The refolds were then filtered
and purified first by ion exchange using a Poros50HQTM col-
umn (GE Healthcare, Buckinghamshire, U.K.) and second by gel
filtration directly into crystallization buffer (10 mM Tris pH8.1
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
270 Amandine Bovay et al. Eur. J. Immunol. 2018. 48: 258–272
and 10 mM NaCl) or PBS buffer (137 mM NaCl, 3 mM KCl, 8 mM
Na2HPO4, 1mMKH2PO4) using a Superdex200HRTM column (GE
Healthcare, Buckinghamshire, U.K.). Protein quality was analyzed
by Coomassie-stained SDS-PAGE, either under non-reducing or
reducing conditions. HLA-A*0201 was refolded with the peptides
LLWNGPMAV (A2/LLW) or LLWAGPMAV (A2/LLW-4A).
Crystallization, diffraction data collection, and model
refinement
All protein crystals were grown at 18°C by vapor diffusion via the
“sitting drop” technique. 200 nL of each pMHC (20 mg/mL) in
crystallization buffer was added to 200 nL of reservoir solution.
A2/LLW crystals were grown in 0.1 M Hepes, pH7, 0.2 M ammo-
nium sulphate, 20%PEG 4000. All crystals were soaked in 30%
ethylene glycol before cryo-cooling. All crystallization screens and
optimization experiments were completed using an Art-Robbins
Gryphon dispensing robot (Alpha Biotech Ltd., UK). Data were
collected at 100 K at the Diamond Light Source (Oxfordshire, UK)
as described previously [40]. All data sets were collected at awave-
length of 0.98 A˚ using an ADSC Q315 CCD detector. Reflection
intensities were estimated with the XIA2 package, and the data
were scaled, reduced, and analyzed with the SCALA and CCP4
package. Structures were solvedwithmolecular replacement using
PHASER. A solution could be obtained with a search model taken
from Protein Data Bank entry 5EU5. Sequences were adjusted
with COOT, and the models were refined with REFMAC5. Graph-
ical representations were prepared with PyMOL. The reflection
data and final model coordinates were deposited in the Protein
Data Bank (PDB code: 5N6B).
Measuring the thermal stability of
HLA-A*0201–peptide complexes
Thermal stability of A2/peptide complexes was assessed by CD
spectroscopy monitoring the change of ellipticities  at 218nm
where the spectra exhibit a minimum. Data were collected on
an Aviv 215 spectrometer (Aviv Biomedical Inc., Lakewood, NJ)
equipped with a thermostated cell holder using a 1 mm quartz
cell. Proteins were dissolved in PBS at c = 3.5 μM. Denatura-
tion was monitored from 4°C up to a temperature when protein
precipitation occurred using a gradient of 0.5°C/min. Melting
curves were analyzed assuming a two-state native (N) to dena-
tured (D) transition N3 ↔ 3D with the melting temperature and
van’t Hoff’s enthalpy at the midpoint of the transition as fitting
parameters [41, 42].
Modeling the TCR-p-MHC complex
The 3D structure of the TRAV12-2/TRBV9 TCR in complex with
HLA-A2 and the LLWNGPMAV peptide was modeled from three
experimental structures: 3HG1 [18] and 4QOK [43], containing
a complex between the TRAV12-2/TRBC1 TCR in complex with
HLA-A2 and the ELAGIGILTV or EAAGIGILTV peptides, respec-
tively, and the experimental structure obtained in this study for
the complex between HLA-A2 and the LLWNGPMAV peptide. The
sequence alignment between TRBV9 and TRBC1 was performed
using the MUSCLE program [44]. The sequence identity between
the variable part of the TRBV9 and TRBC1 TCR beta chains is 30%.
Based on this sequence alignment, the model was obtained using
the Modeller program [45, 46]. 1000 models were generated by
satisfaction of spatial restraints through minimization and simu-
lated annealing, and the model with the best Modeller objective
function was retained. Molecules were visualized and analyzed
using UCSF Chimera [47].
The model of A2/LLW in complex with the MEL5 TCR was
obtained with the Modeller program, following the method
described above to obtain the structural model of A2/LLW with
the YF5048 TCR. In this case, however, we used our experimen-
tal structure of the A2/LLW as a template for the HLA/peptide
domain and the experimental structure of the complex between
A2/ELA and MEL5 (PDB code: 3HG1) as a template for the MEL5
TCR.
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